Overview
Janssen-Cilag Polska is a pharmaceutical company that focuses on innovative medicine, particularly in oncology, immunology, and neuroscience. It has developed and received FDA approval for several treatments, including RYBREVANT FASPRO™ for EGFR-mutated non-small cell lung cancer, CAPLYTA® for major depressive disorder, and DARZALEX FASPRO® for high-risk smoldering multiple myeloma. The company also acquired Halda Therapeutics to enhance cancer treatment options.
Financials
Revenue history (in m)
From the notes
| Current income tax (CIT due) | $5,599,470 |
Filing timeliness
6 of 6 financial statements were filed late (the longest delay 237 days for 2022). All were audited by a statutory auditor.
- 202528/09/2026
- 202416/12/2025
- 202313/08/2024
- 202208/03/2024
- 202126/10/2022
- 202011/01/2022
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
Industry
- Advertising agencies (73.11.Z) Primary
Offer
- Oncology medicines
- Immunology medicines
- Neurology medicines
- Cardiopulmonary medicines
Websites
- jnjmedicalcloud.plWitaj na J&J Medical CloudGoogle Tag ManagerCloudflare
Public procurement
915 tenders recorded as contractor: 175 national ($11,419,793) and 740 EU ($1,313,069,016).
| Publication date | Subject | Amount | Contracting authority | |
|---|---|---|---|---|
| Nov 17, 2026 | Supply of various medicines, including programme medicines | –– | Szpital Wojewódzki Im. Jana Pawła II w Bełchatowie | |
| Nov 17, 2026 | Delivery of medicinal products (drug programmes) for Szpital Kolejowy im. dr med. Włodzimierza Roeflera at ul. Warsztatowa 1 in Pruszków. | $213.6K$213,630 | Mazowieckie Centrum Rehabilitacji Stocer sp. z o.o. | |
| Nov 13, 2026 | DFP.271.137.2026.EP Supply of medicinal products | $775.1K$775,081 | Szpital Uniwersytecki w Krakowie |
The company is the contractor in 289 public sector contracts, worth USD 84.03m in total. They were signed with 83 public buyers. The largest number (3) were signed with Uniwersyteckie Centrum Kliniczne.
| Signed on | Subject | Amount | Public buyer | |
|---|---|---|---|---|
| Nov 16, 2026 | Dostawa produktów leczniczych dla pacjentów hospitalizowanych oraz stosowanych do realizacji świadczeń z zakresu terapeutycznych programów lekowych B.1, B.56, B.106.
Pakiet nr 13- Apalutamid 60mg x 130 tabl., Apalutamid 240mg x 30 tabl. | $86,839 | Wielospecjalistyczny Szpital Miejski Im. Józefa Strusia w Poznaniu | |
| Nov 16, 2026 | Supply of medicinal products | $79,687 | Górnośląskie Centrum Medyczne Im. Prof. Leszka Gieca Śląskiego Uniwersytetu Medycznego w Katowicach | |
| Nov 13, 2026 | RYBREVANT350MG X 1FIOL - 4 OP. | $1,945 | Świętokrzyskie Centrum Onkologii Samodzielny Publiczny Zakład Opieki Zdrowotnej w Kielcach |
Authorized Representatives
Manner of representation
In the case of a management board consisting of one or two members, the members of the management board represent the company individually before public authorities and third parties, in court and out of court. In the case where the company's management board consists of three or more members, the company is represented by two members of the management board acting jointly, or by a member of the management board acting jointly with an independent commercial proxy or any of the joint commercial proxies.
Ownership
| Owner | Share value | Stake |
|---|---|---|
Johnson & Johnson International Financial Services Company | $6,766,612.64 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Capital group
The company belongs to the Johnson & Johnson (United States) group, which is its direct owner. The group has 210 companies, 200 of them abroad.
| Name | Country |
|---|---|
| Abiomed Europe GmbH | |
| Abiomed Japan K.K. | |
| Abiomed R&D, Inc. | |
| Abiomed, Inc. | |
| Acclarent, Inc. |
Bank accounts
Registered as a VAT taxpayer on 2003-10-31.
76 1030 1508 0000 0008 1088 7079
51 1030 1508 0000 0008 1088 7044
48 1030 1508 0000 0008 1088 7001
Debt
No entries in the National Debtors Register (KRZ).
Real estate
| Type | Amount |
|---|---|
Buildings and premises | PLN 37,728PLN 37,728 |
MSiG notices
| Publication date | Event | |
|---|---|---|
| Feb 6, 2019 | Merger plan |
Public aid
No public aid cases recorded in the last 10 years.
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Astrazeneca Pharma Poland sp. z o.o. | $466,142,370.29 | astrazeneca.pl | ||
| Novartis Poland sp. z o.o. | $378,147,128.47 | novartis.com | ||
| Bristol-Myers Squibb Polska sp. z o.o. | $230,722,737.87 | bms.com | ||
| Takeda Pharma sp. z o.o. | $246,400,594.27 | takeda.com | ||
| Accord Healthcare Polska sp. z o.o. | $178,502,388.11 | accord-healthcare.pl | ||
| Gilead Sciences Poland sp. z o.o. | $150,844,944.19 | gilead.com | ||
| Amgen sp. z o.o. | $145,068,009.51 | amgen.pl | ||
| Ipsen Poland sp. z o.o. | $94,814,847.87 | ipsen.com | ||
| Medac Gesellschaft Fur Klinische Spezialpraparate M.B.H. Branch (foreign co.) | $55,460,856.07 | medac.pl | ||
| Servier Polska sp. z o.o. | $44,419,387.24 | servier.pl |
Change history
| Date | Event | |
|---|---|---|
| 2017-01-27 | PKD change (Added: 46.46.Z) | |
| 2015-03-17 | Switch to PKD 2007 (6 PKD 1997 codes → 8 PKD 2007 codes) | |
| 2007-08-21 | Address change (Szyszkowa 20, 02-285, Warszawa → Iłżecka 24, 02-135, Warszawa) | |
| 2003-01-16 | Share capital increase (50,000.00 PLN → 25,050,000.00 PLN) | |
| 2003-01-16 | Name change (Jannsen-Cilag Polska → Janssen-Cilag Polska) |
FAQ
Last updated: 2026-11-03